https://www.cancernetwork.com/view/fda-approval-of-essential-thrombocythemia-drug-is-important-milestone-2026-09-02T21:00:00Z2026-09-02T21:00:00Z https://www.cancernetwork.com/view/will-ai-steer-oncologists-or-will-oncologists-steer-ai-2026-09-02T20:00:00Z2026-09-02T20:00:00Z https://www.cancernetwork.com/view/what-does-personalization-of-radiopharmaceutical-therapy-require-2026-09-02T18:00:00Z2026-09-02T18:00:00Z https://www.cancernetwork.com/view/eu-approves-t-dxd-pertuzumab-for-frontline-her2-metastatic-breast-cancer2026-09-02T16:00:00Z2026-09-02T16:00:00Z https://www.cancernetwork.com/view/zanidatamab-plus-chemotherapy-extends-os-in-first-line-her2-advanced-gea2026-09-02T15:00:00Z2026-09-02T15:00:00Z https://www.cancernetwork.com/view/overlapping-toxicities-and-long-term-survivorship-needs2026-09-02T14:27:11.711Z2026-09-02T14:27:11.711Z https://www.cancernetwork.com/view/oral-adherence-and-access-in-long-term-targeted-therapy2026-09-02T14:27:09.987Z2026-09-02T14:27:09.987Z https://www.cancernetwork.com/view/preparing-patients-for-bispecific-antibody-based-first-line-therapy2026-09-02T14:27:08.296Z2026-09-02T14:27:08.296Z https://www.cancernetwork.com/view/supporting-patients-when-first-line-therapy-intensifies2026-09-02T14:27:06.901Z2026-09-02T14:27:06.901Z https://www.cancernetwork.com/view/managing-diarrhea-and-nutrition-on-first-line-egfr-therapy2026-09-02T14:27:05.461Z2026-09-02T14:27:05.461Z https://www.cancernetwork.com/view/grading-toxicity-and-preserving-dose-intensity-in-nsclc2026-09-02T14:27:04.162Z2026-09-02T14:27:04.162Z https://www.cancernetwork.com/view/telephone-triage-and-early-recognition-of-pneumonitis2026-09-02T14:27:02.661Z2026-09-02T14:27:02.661Z https://www.cancernetwork.com/view/structuring-caregiver-education-at-treatment-initiation2026-09-02T14:27:01.135Z2026-09-02T14:27:01.135Z https://www.cancernetwork.com/view/preventing-and-managing-dermatologic-toxicity-in-egfr-mutated-nsclc2026-09-02T14:26:59.442Z2026-09-02T14:26:59.442Z https://www.cancernetwork.com/view/v940-plus-pembrolizumab-in-melanoma-mechanism-data-and-safety2026-09-02T14:00:00Z2026-09-02T14:00:00Z https://www.cancernetwork.com/view/novel-agent-earns-fda-breakthrough-therapy-designation-for-hpv-oropharyngeal-cancer2026-09-02T13:00:00Z2026-09-02T13:00:00Z https://www.cancernetwork.com/view/case-discussion-selecting-bcma-bispecific-therapy-for-a-patient-with-relapsed-refractory-multiple-myeloma-and-limited-access-to-car-t2026-09-02T12:05:00Z2026-09-02T12:05:00Z https://www.cancernetwork.com/view/debate-the-future-role-of-bcma-bispecific-antibodies-in-later-line-relapsed-refractory-multiple-myeloma2026-09-02T12:00:00Z2026-09-02T12:00:00Z https://www.cancernetwork.com/view/speaking-with-one-voice-for-world-radiotherapy-awareness-day2026-09-02T12:00:00Z2026-09-02T12:00:00Z https://www.cancernetwork.com/view/what-do-clinicians-get-right-about-radiopharmaceutical-therapy-2026-09-01T19:00:00Z2026-09-01T19:00:00Z https://www.cancernetwork.com/view/capivasertib-and-emerging-options-in-the-post-cdk4-6-inhibitor-setting2026-09-01T18:30:47.735Z2026-09-01T18:30:47.735Z https://www.cancernetwork.com/view/managing-adverse-events-with-capivasertib-plus-fulvestrant2026-09-01T18:30:46.094Z2026-09-01T18:30:46.094Z https://www.cancernetwork.com/view/survival-after-prior-cdk4-6-inhibition-and-delaying-chemotherapy2026-09-01T18:30:44.593Z2026-09-01T18:30:44.593Z https://www.cancernetwork.com/view/post-progression-therapy-crossover-and-interpreting-survival-endpoints2026-09-01T18:30:43.194Z2026-09-01T18:30:43.194Z https://www.cancernetwork.com/view/final-overall-survival-results-in-the-intention-to-treat-population2026-09-01T18:30:41.933Z2026-09-01T18:30:41.933Z https://www.cancernetwork.com/view/final-overall-survival-in-the-pik3ca-akt1-pten-altered-population2026-09-01T18:30:40.614Z2026-09-01T18:30:40.614Z https://www.cancernetwork.com/view/statistical-design-of-the-capitello-291-final-survival-analysis2026-09-01T18:30:38.984Z2026-09-01T18:30:38.984Z https://www.cancernetwork.com/view/primary-progression-free-survival-results-from-capitello-2912026-09-01T18:30:37.709Z2026-09-01T18:30:37.709Z https://www.cancernetwork.com/view/capitello-291-study-design-and-intermittent-capivasertib-dosing2026-09-01T18:30:36.035Z2026-09-01T18:30:36.035Z https://www.cancernetwork.com/view/how-is-ai-monitoring-inpatient-risk-and-reducing-documentation-burden-2026-09-01T18:00:00Z2026-09-01T18:00:00Z https://www.cancernetwork.com/view/how-is-ai-shaping-patient-centered-multidisciplinary-oncology-care-2026-09-01T17:00:00Z2026-09-01T17:00:00Z https://www.cancernetwork.com/view/rezatapopt-yields-responses-supports-nda-plan-in-ovarian-cancer2026-09-01T16:00:31.057Z2026-09-01T16:00:31.057Z https://www.cancernetwork.com/view/signatera-ctdna-test-shows-superior-mrd-assessment-in-lymphoma2026-09-01T15:30:00Z2026-09-01T15:30:00Z https://www.cancernetwork.com/view/fda-receives-snda-for-selinexor-plus-ruxolitinib-in-myelofibrosis2026-09-01T15:00:00Z2026-09-01T15:00:00Z https://www.cancernetwork.com/view/no-new-safety-signals-seen-with-v940-plus-pembrolizumab-in-melanoma2026-09-01T14:00:00Z2026-09-01T14:00:00Z https://www.cancernetwork.com/view/top-9-takeaways-from-asco-s-2026-breast-cancer-surveillance-update2026-09-01T14:00:00Z2026-09-01T14:00:00Z https://www.cancernetwork.com/view/finding-support-through-the-relapsed-refractory-multiple-myeloma-journey2026-09-01T12:05:00Z2026-09-01T12:05:00Z https://www.cancernetwork.com/view/multidisciplinary-support-in-relapsed-refractory-multiple-myeloma2026-09-01T12:00:00Z2026-09-01T12:00:00Z https://www.cancernetwork.com/view/biomarker-testing-and-treatment-selection-in-hr-her2-mbc2026-08-31T21:09:20.878Z2026-08-31T21:09:20.878Z https://www.cancernetwork.com/view/second-line-treatment-considerations-in-hr-her2-mbc2026-08-31T21:08:35.481Z2026-08-31T21:08:35.481Z https://www.cancernetwork.com/view/spartalizumab-triplet-improves-os-in-braf-melanoma-combi-i-final-analysis2026-08-31T20:00:00Z2026-08-31T20:00:00Z https://www.cancernetwork.com/view/navigating-molecular-testing-workflow-and-turnaround-time-in-nsclc2026-08-31T19:05:00Z2026-08-31T19:05:00Z https://www.cancernetwork.com/view/distinguishing-her2-mutation-from-amplification-and-overexpression-in-nsclc2026-08-31T19:00:00Z2026-08-31T19:00:00Z https://www.cancernetwork.com/view/from-wish-list-to-reality-ai-tools-already-working-in-matasar-s-practice2026-08-31T18:00:00Z2026-08-31T18:00:00Z https://www.cancernetwork.com/view/savolitinib-combo-boosts-pfs-in-first-line-egfr-mutant-nsclc-trial2026-08-31T16:00:14.675Z2026-08-31T16:00:14.675Z https://www.cancernetwork.com/view/autogene-cevumeran-trial-terminated-in-resected-colorectal-cancer2026-08-31T14:57:26.933Z2026-08-31T14:57:26.933Z https://www.cancernetwork.com/view/v940-plus-pembrolizumab-cuts-melanoma-recurrence-risk-by-49-2026-08-31T14:00:00Z2026-08-31T14:00:00Z https://www.cancernetwork.com/view/fda-oks-ropeginterferon-alfa-for-essential-thrombocytopenia2026-08-31T12:38:30.422Z2026-08-31T12:38:30.422Z https://www.cancernetwork.com/view/proactive-patient-education-across-first-line-egfr-regimens2026-08-31T12:02:00Z2026-08-31T12:02:00Z https://www.cancernetwork.com/view/baseline-nursing-assessment-before-first-line-egfr-therapy2026-08-31T12:01:00Z2026-08-31T12:01:00Z https://www.cancernetwork.com/view/keynote-966-long-term-follow-up-and-comparative-safety-of-chemoimmunotherapy2026-08-31T12:00:00Z2026-08-31T12:00:00Z https://www.cancernetwork.com/view/how-mentorship-and-peer-support-help-oncologists-avoid-burnout2026-08-31T12:00:00Z2026-08-31T12:00:00Z https://www.cancernetwork.com/view/is-digital-pathology-ready-to-transform-hematologic-diagnosis-2026-08-30T18:00:00Z2026-08-30T18:00:00Z https://www.cancernetwork.com/view/asco-issues-first-living-guideline-for-recurrent-ovarian-cancer-treatment2026-08-30T16:00:00Z2026-08-30T16:00:00Z https://www.cancernetwork.com/view/how-can-oncologists-start-experimenting-with-ai-tools-today-2026-08-29T18:00:00Z2026-08-29T18:00:00Z https://www.cancernetwork.com/view/novel-soft-tissue-sarcoma-treatment-receives-fda-fast-track-designation2026-08-29T14:00:00Z2026-08-29T14:00:00Z https://www.cancernetwork.com/view/fda-approves-rusfertide-in-polycythemia-vera2026-08-28T22:52:25.347Z2026-08-28T22:52:25.347Z https://www.cancernetwork.com/view/how-v940-works-mechanism-of-the-personalized-melanoma-vaccine2026-08-28T22:00:00Z2026-08-28T22:00:00Z https://www.cancernetwork.com/view/how-is-ai-already-being-used-in-blood-cancer-tumor-boards-2026-08-28T18:00:00Z2026-08-28T18:00:00Z https://www.cancernetwork.com/view/paxalisib-achieves-100-clinical-benefit-rate-in-metastatic-tnbc2026-08-28T17:00:00Z2026-08-28T17:00:00Z https://www.cancernetwork.com/view/individualizing-car-t-cell-therapy-vs-bispecific-antibodies-in-relapsed-multiple-myeloma2026-08-28T16:00:00Z2026-08-28T16:00:00Z https://www.cancernetwork.com/view/where-ciltacabtagene-autoleucel-belongs-in-sequencing2026-08-28T15:44:19.889Z2026-08-28T15:44:19.889Z https://www.cancernetwork.com/view/asco-warns-of-critical-ifosfamide-shortage-threatening-cancer-treatment2026-08-28T15:00:00Z2026-08-28T15:00:00Z https://www.cancernetwork.com/view/adi-212-receives-fda-ind-clearance-for-castration-resistant-prostate-cancer2026-08-28T14:30:00Z2026-08-28T14:30:00Z https://www.cancernetwork.com/view/botensilimab-balstilimab-elicits-major-pathologic-responses-in-colon-cancer2026-08-28T14:00:00Z2026-08-28T14:00:00Z https://www.cancernetwork.com/view/celmod-mechanism-and-differentiation-from-imids-in-multiple-myeloma2026-08-28T12:15:00Z2026-08-28T12:15:00Z https://www.cancernetwork.com/view/pi3k-akt-pathway-biology-capivasertib-and-biomarker-testing2026-08-28T12:03:00Z2026-08-28T12:03:00Z https://www.cancernetwork.com/view/evolving-post-cdk4-6-inhibitor-landscape-in-advanced-breast-cancer2026-08-28T12:01:00Z2026-08-28T12:01:00Z https://www.cancernetwork.com/view/managing-multifocal-bclc-c-hcc-with-portal-vein-invasion-and-variceal-history2026-08-28T12:00:00Z2026-08-28T12:00:00Z https://www.cancernetwork.com/view/how-will-iberdomide-s-approval-and-other-celmods-impact-multiple-myeloma-2026-08-28T12:00:00Z2026-08-28T12:00:00Z https://www.cancernetwork.com/view/introduction-and-overview-of-celmods-in-multiple-myeloma2026-08-28T12:00:00Z2026-08-28T12:00:00Z https://www.cancernetwork.com/view/five-key-posters-from-the-2026-sno-asco-cns-metastases-conference2026-08-27T21:00:00Z2026-08-27T21:00:00Z https://www.cancernetwork.com/view/matthew-matasar-md-lymphoma-specialist-navigating-the-immunotherapy-era2026-08-27T20:00:00Z2026-08-27T20:00:00Z https://www.cancernetwork.com/view/daratumumab-combo-sets-new-os-benchmark-in-transplant-ineligible-ndmm2026-08-27T18:00:00Z2026-08-27T18:00:00Z https://www.cancernetwork.com/view/how-significant-is-the-approval-of-daraxonrasib-in-pancreatic-cancer-2026-08-27T17:00:00Z2026-08-27T17:00:00Z https://www.cancernetwork.com/view/soquelitinib-monotherapy-yields-durable-responses-in-peripheral-t-cell-lymphoma2026-08-27T16:00:00Z2026-08-27T16:00:00Z https://www.cancernetwork.com/view/snda-for-gedatolisib-submitted-to-fda-in-pik3ca-mutant-breast-cancer2026-08-27T15:09:45.537Z2026-08-27T15:09:45.537Z https://www.cancernetwork.com/view/can-delayed-gadopiclenol-mri-improve-brain-metastasis-detection-before-srs2026-08-27T14:00:00Z2026-08-27T14:00:00Z https://www.cancernetwork.com/view/where-do-celmods-fit-with-car-t-cells-and-bispecifics-in-multiple-myeloma-2026-08-27T12:00:00Z2026-08-27T12:00:00Z https://www.cancernetwork.com/view/biomarker-independent-adc-rina-s-advances-to-phase-3-in-endometrial-cancer2026-08-26T20:00:00Z2026-08-26T20:00:00Z https://www.cancernetwork.com/view/adaptive-planning-trial-aims-improve-radiosurgery-precision-brain-metastases2026-08-26T18:00:00Z2026-08-26T18:00:00Z https://www.cancernetwork.com/view/rewriting-the-prescription-can-exercise-optimize-treatment-outcomes-in-oncology-2026-08-26T17:00:00Z2026-08-26T17:00:00Z https://www.cancernetwork.com/view/fda-approves-daraxonrasib-for-previously-treated-metastatic-pancreatic-cancer2026-08-26T14:56:52.332Z2026-08-26T14:56:52.332Z https://www.cancernetwork.com/view/venetoclax-hma-combo-demonstrates-real-world-efficacy-in-unfit-aml2026-08-26T14:00:00Z2026-08-26T14:00:00Z https://www.cancernetwork.com/view/celmod-wins-landmark-approval-in-relapsed-refractory-multiple-myeloma2026-08-26T13:00:00Z2026-08-26T13:00:00Z https://www.cancernetwork.com/view/debate-class-effect-versus-meaningful-differences-among-bcma-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-08-26T12:05:00Z2026-08-26T12:05:00Z https://www.cancernetwork.com/view/debate-car-t-cell-therapy-versus-bcma-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-08-26T12:00:00Z2026-08-26T12:00:00Z https://www.cancernetwork.com/view/exploring-the-future-of-radiopharmaceutical-therapy-in-oncology2026-08-26T12:00:00Z2026-08-26T12:00:00Z https://www.cancernetwork.com/view/the-importance-of-multidisciplinary-tumor-boards-in-brain-metastases-care2026-08-25T21:00:00Z2026-08-25T21:00:00Z https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-eras-0015-for-pancreatic-adenocarcinoma2026-08-25T20:30:35.640Z2026-08-25T20:30:35.640Z https://www.cancernetwork.com/view/lenvatinib-dose-reductions-help-sustain-therapy-in-endometrial-cancer2026-08-25T20:00:00Z2026-08-25T20:00:00Z https://www.cancernetwork.com/view/enfortumab-vedotin-combo-shows-real-world-benefit-in-urothelial-carcinoma2026-08-25T17:00:00Z2026-08-25T17:00:00Z https://www.cancernetwork.com/view/fda-approves-zanidatamab-based-regimens-for-first-line-her2-gastric-cancers2026-08-25T15:26:09.234Z2026-08-25T15:26:09.234Z https://www.cancernetwork.com/view/sevabertinib-earns-japanese-approval-across-all-lines-in-her2-mutant-nsclc2026-08-25T15:00:00Z2026-08-25T15:00:00Z https://www.cancernetwork.com/view/from-moonshot-to-ground-shot-advancing-cns-metastases-care2026-08-25T14:00:00Z2026-08-25T14:00:00Z https://www.cancernetwork.com/view/preparing-for-advanced-therapy-in-relapsed-refractory-multiple-myeloma2026-08-25T12:05:00Z2026-08-25T12:05:00Z https://www.cancernetwork.com/view/managing-radiation-necrosis-is-next-frontier-in-stereotactic-radiosurgery2026-08-25T12:00:00Z2026-08-25T12:00:00Z https://www.cancernetwork.com/view/evolving-treatment-goals-in-relapsed-refractory-multiple-myeloma2026-08-25T12:00:00Z2026-08-25T12:00:00Z https://www.cancernetwork.com/view/lenvatinib-combo-holds-ground-against-her2-adcs-in-endometrial-cancer2026-08-24T20:00:00Z2026-08-24T20:00:00Z https://www.cancernetwork.com/view/expanding-indications-for-stereotactic-radiosurgery-in-brain-metastases2026-08-24T18:00:00Z2026-08-24T18:00:00Z